The vitamin K-antagonism of salicylate and warfarin.
When administered in high dosages, salicylate acts as a vitamin K-antagonist: it induces a decrease of the plasma concentration of the Gla-containing coagulation factors and an accumulation of microsomal substrates for vitamin K-dependent carboxylase in the liver and in the lung. In vitro the drugs inhibit the DTT-dependent reductases which mediate the reduction of vitamin K epoxide and vitamin K quinone. NADH-dependent reductase and vitamin K-dependent carboxylase are not inhibited.
D000818:Animals; D001779:Blood Coagulation Factors / Q000097:blood; D002262:Carboxy-Lyases / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D051381:Rats; D012459:Salicylates / Q000494:pharmacology*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000494:pharmacology*
D001779:Blood Coagulation Factors; D012459:Salicylates; D014812:Vitamin K; D014859:Warfarin; D010088:Oxidoreductases; D002262:Carboxy-Lyases